ClinicalTrials.Veeva

Menu
A

American Research Corporation at the Texas Liver Institute | San Antonio, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

EDP-305
BI 685509
Elafibranor
Obeticholic Acid
Ursodeoxycholic Acid
Cilofexor
Firsocostat
ALN-HSD
EYE103
HM15211

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 40 total trials

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis (ELFIDENCE)

The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) and cirrhosis (scarring of the liver).PBC is a slowly progressiv...

Enrolling
Primary Biliary Cholangitis (PBC)
Drug: Elafibranor
Other: Matched 80 mg placebo

This study is researching an investigational drug called ALN-HSD (called "study drug"). This study is focused on participants who are known to have n...

Enrolling
Non-alcoholic Steatohepatitis (NASH)
Metabolic Dysfunction Associated Steatohepatitis (MASH)
Drug: Placebo
Drug: ALN-HSD

The participants in this study will have confirmed PBC with inadequate response or intolerance to Ursodeoxycholic acid (UDCA), which is a medication...

Enrolling
Primary Biliary Cholangitis
Other: Placebo
Drug: Elafibranor

This study will evaluate the effects of elafibranor (the study drug) in participants with Primary Sclerosing Cholangitis (PSC). PSC is a rare disease...

Active, not recruiting
Primary Sclerosing Cholangitis
Drug: Placebo Matched to Elafibranor 80 mg
Drug: Placebo Matched to Elafibranor 120 mg

EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active...

Enrolling
Diabetic Macular Edema (DME)
Drug: EYE103
Drug: Ranibizumab

This study is open to people with cirrhosis caused by a liver disease called MASH (metabolic dysfunction-associated steatohepatitis). The purpose of...

Enrolling
Metabolic Dysfunction Associated Steatohepatitis (MASH)
Compensated Liver Cirrhosis
Drug: BI 770371
Drug: Placebo for BI 770371

This study is open to adults between 18 and 80 years of age. People with a body mass index (BMI) between 18 and 42 kg/m\^2 can take part. Women can o...

Enrolling
Healthy
Liver Diseases
Drug: Zongertinib (BI 1810631)

The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects with Prim...

Enrolling
Hepatic Impairment
Compensated Cirrhosis
Drug: Seladelpar 10 mg or less
Drug: Seladelpar 10 mg

This is a Phase IIa, Randomized, Double-blind, Placebo-controlled, multi-center Proof-of-Concept (POC) Trial in subjects with severe Alopecia Areata.

Active, not recruiting
Alopecia Areata
Drug: ADX-914
Drug: Placebo

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

Active, not recruiting
Primary Biliary Cirrhosis
Drug: Seladelpar 10 mg Capsule
Drug: Seladelpar 5 mg Capsule

Study to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (...

Active, not recruiting
Primary Biliary Cholangitis
Drug: Obeticholic Acid placebo
Drug: Obeticholic Acid 5 mg

This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH

Enrolling
NASH - Nonalcoholic Steatohepatitis
Drug: HM15211
Drug: Placebo of HM15211

Trial sponsors

Boehringer Ingelheim logo
Gilead Sciences logo
Enanta Pharmaceuticals logo
I
Ipsen logo
E
Regeneron Pharmaceuticals logo
A
A
AstraZeneca logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems